MediciNova Statistics
Total Valuation
MediciNova has a market cap or net worth of $92.54 million. The enterprise value is $67.24 million.
| Market Cap | 92.54M |
| Enterprise Value | 67.24M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MediciNova has 49.22 million shares outstanding. The number of shares has increased by 0.21% in one year.
| Current Share Class | 49.22M |
| Shares Outstanding | 49.22M |
| Shares Change (YoY) | +0.21% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.87% |
| Owned by Institutions (%) | 10.55% |
| Float | 42.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 112.29 |
| Forward PS | 1,240.43 |
| PB Ratio | 2.77 |
| P/TBV Ratio | 4.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 84.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.75, with a Debt / Equity ratio of 0.00.
| Current Ratio | 8.75 |
| Quick Ratio | 8.58 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.56% and return on invested capital (ROIC) is -17.52%.
| Return on Equity (ROE) | -25.56% |
| Return on Assets (ROA) | -16.41% |
| Return on Invested Capital (ROIC) | -17.52% |
| Return on Capital Employed (ROCE) | -31.62% |
| Weighted Average Cost of Capital (WACC) | 7.71% |
| Revenue Per Employee | $153,414 |
| Profits Per Employee | -$1.79M |
| Employee Count | 6 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MediciNova has paid $5,994 in taxes.
| Income Tax | 5,994 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +47.24% in the last 52 weeks. The beta is 0.63, so MediciNova's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +47.24% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.50 |
| Relative Strength Index (RSI) | 43.86 |
| Average Volume (20 Days) | 879,336 |
Short Selling Information
The latest short interest is 374,674, so 0.76% of the outstanding shares have been sold short.
| Short Interest | 374,674 |
| Short Previous Month | 369,685 |
| Short % of Shares Out | 0.76% |
| Short % of Float | 0.89% |
| Short Ratio (days to cover) | 5.59 |
Income Statement
In the last 12 months, MediciNova had revenue of $920,481 and -$10.75 million in losses. Loss per share was -$0.22.
| Revenue | 920,481 |
| Gross Profit | 347,443 |
| Operating Income | -11.85M |
| Pretax Income | -10.75M |
| Net Income | -10.75M |
| EBITDA | -11.83M |
| EBIT | -11.85M |
| Loss Per Share | -$0.22 |
Balance Sheet
The company has $25.42 million in cash and $117,038 in debt, with a net cash position of $25.30 million or $0.51 per share.
| Cash & Cash Equivalents | 25.42M |
| Total Debt | 117,038 |
| Net Cash | 25.30M |
| Net Cash Per Share | $0.51 |
| Equity (Book Value) | 37.27M |
| Book Value Per Share | 0.76 |
| Working Capital | 22.96M |
Cash Flow
In the last 12 months, operating cash flow was -$9.11 million and capital expenditures -$13,724, giving a free cash flow of -$9.12 million.
| Operating Cash Flow | -9.11M |
| Capital Expenditures | -13,724 |
| Depreciation & Amortization | 19,138 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.12M |
| FCF Per Share | -$0.19 |
Margins
| Gross Margin | 37.75% |
| Operating Margin | -1,287.41% |
| Pretax Margin | -1,167.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MediciNova does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.21% |
| Shareholder Yield | -0.21% |
| Earnings Yield | -10.40% |
| FCF Yield | -8.83% |
Analyst Forecast
The average price target for MediciNova is $8.25, which is 338.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.25 |
| Price Target Difference | 338.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 370.58% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediciNova has an Altman Z-Score of -2.69 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.69 |
| Piotroski F-Score | 3 |